Partnering

SYNIMMUNE offers the following partnering opportunities to collaboration partners from the pharmaceutical and biotechnology industry:

·         Clinical Development and commercialisation partnership for FLYSYN (based on interim clinical data available in mid-2018)

·         Development and commercialisation partnership for TACSYN for preclinical and further clinical development

·         Research and licensing partnerships for the application of SYNIMMUNE’s proprietary bispecific antibody platform to new targets in diverse indications